JPS5874615A - 癌治療用組成物 - Google Patents
癌治療用組成物Info
- Publication number
- JPS5874615A JPS5874615A JP56174406A JP17440681A JPS5874615A JP S5874615 A JPS5874615 A JP S5874615A JP 56174406 A JP56174406 A JP 56174406A JP 17440681 A JP17440681 A JP 17440681A JP S5874615 A JPS5874615 A JP S5874615A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- cancer
- cells
- brain tissue
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 21
- 206010028980 Neoplasm Diseases 0.000 title description 52
- 201000011510 cancer Diseases 0.000 title description 40
- 238000011282 treatment Methods 0.000 title description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 210000005013 brain tissue Anatomy 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 210000005171 mammalian brain Anatomy 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 3
- 241001455213 Leopardus pardalis Species 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 58
- 210000001519 tissue Anatomy 0.000 description 28
- 108010034634 Repressor Proteins Proteins 0.000 description 15
- 102000009661 Repressor Proteins Human genes 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 241000699800 Cricetinae Species 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108700005075 Regulator Genes Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012830 cancer therapeutic Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100021255 Small acidic protein Human genes 0.000 description 1
- 101710174775 Small acidic protein Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- -1 helical Chemical compound 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 210000005132 reproductive cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14541980A | 1980-05-01 | 1980-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5874615A true JPS5874615A (ja) | 1983-05-06 |
Family
ID=22513026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56174406A Pending JPS5874615A (ja) | 1980-05-01 | 1981-10-30 | 癌治療用組成物 |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5874615A (OSRAM) |
| CA (1) | CA1175741A (OSRAM) |
| CH (1) | CH655659B (OSRAM) |
| DE (1) | DE3116733A1 (OSRAM) |
| ES (1) | ES501835A0 (OSRAM) |
| FR (1) | FR2481602A1 (OSRAM) |
| GB (1) | GB2075988B (OSRAM) |
| MX (1) | MX6826E (OSRAM) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2717227A (en) * | 1954-12-22 | 1955-09-06 | Helen L Dawson | Composition containing nerve tissue extract and process of producing such extract |
| DE1095464B (de) * | 1956-05-22 | 1960-12-22 | Univ Tulane | Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten |
-
1981
- 1981-04-28 DE DE19813116733 patent/DE3116733A1/de not_active Withdrawn
- 1981-04-29 FR FR8108520A patent/FR2481602A1/fr active Granted
- 1981-04-30 GB GB8113341A patent/GB2075988B/en not_active Expired
- 1981-04-30 MX MX819434U patent/MX6826E/es unknown
- 1981-04-30 ES ES501835A patent/ES501835A0/es active Granted
- 1981-05-01 CH CH286381A patent/CH655659B/de not_active IP Right Cessation
- 1981-10-22 CA CA000388472A patent/CA1175741A/en not_active Expired
- 1981-10-30 JP JP56174406A patent/JPS5874615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES8300477A1 (es) | 1982-11-01 |
| ES501835A0 (es) | 1982-11-01 |
| GB2075988B (en) | 1983-09-01 |
| MX6826E (es) | 1986-08-08 |
| GB2075988A (en) | 1981-11-25 |
| FR2481602A1 (fr) | 1981-11-06 |
| CA1175741A (en) | 1984-10-09 |
| DE3116733A1 (de) | 1982-04-01 |
| CH655659B (OSRAM) | 1986-05-15 |
| FR2481602B1 (OSRAM) | 1984-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramer et al. | Restoring function after spinal cord injury: towards clinical translation of experimental strategies | |
| Kokaia et al. | Brain insults in rats induce increased expression of the BDNF gene through differential use of multiple promoters | |
| JPH03503633A (ja) | 遺伝物質を血液脳関門に送る方法 | |
| Cohen et al. | The new genetic medicines | |
| AHLSKOG | Cerebral transplantation for Parkinson's disease: current progress and future prospects | |
| Hefti et al. | Nerve growth factor and Alzheimer's disease | |
| Sun et al. | Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery | |
| Christ et al. | The application of gene therapy to the treatment of erectile dysfunction | |
| Liu et al. | Effects of tail nerve electrical stimulation on the activation and plasticity of the lumbar locomotor circuits and the prevention of skeletal muscle atrophy after spinal cord transection in rats | |
| Martins et al. | Experimental delayed radiation necrosis of the brain: Part 1: Effect of early dexamethasone treatment | |
| RU2099080C1 (ru) | Способ предотвращения развития рака | |
| Connor | Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat. | |
| JPS5874615A (ja) | 癌治療用組成物 | |
| CN112641796B (zh) | 一种缺血性脑卒中的神经保护药物 | |
| AU2010241201A1 (en) | Method for growing human organs, treating diseases, and increasing longevity | |
| Son et al. | Inhibition of γ-irradiation induced adhesion molecules and NO production by alginate in human endothelial cells | |
| Becker | Induced dedifferentiation: a possible alternative to embryonic stem cell transplants | |
| Callaway | Improving neurologic outcomes after out-of-hospital cardiac arrest | |
| US4559228A (en) | Composition and method for the treatment of cancer | |
| AU2006343439B2 (en) | The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form | |
| Guth et al. | Functional deficits and anatomical alterations after high cervical spinal hemisection in the rat | |
| PL188157B1 (pl) | Zastosowanie pozakomórkowych proteinaz | |
| Shikowitz et al. | Histological and molecular analysis of cottontail rabbit papillomavirus-induced papillomas treated with hematoporphyrin derivative photodynamic therapy | |
| US4728511A (en) | Composition and method for the treatment of cancer | |
| AU3441793A (en) | Enzyme castration of animals and tumor treatment |